Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Xponance Inc.

Xponance Inc. increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,456 shares of the biopharmaceutical company's stock after purchasing an additional 1,806 shares during the period. Xponance Inc.'s holdings in Alnylam Pharmaceuticals were worth $5,284,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Intech Investment Management LLC lifted its stake in Alnylam Pharmaceuticals by 6.0% in the 4th quarter. Intech Investment Management LLC now owns 7,573 shares of the biopharmaceutical company's stock worth $1,782,000 after purchasing an additional 428 shares in the last quarter. Horizon Kinetics Asset Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 4.4% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 2,880 shares of the biopharmaceutical company's stock worth $678,000 after purchasing an additional 121 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of Alnylam Pharmaceuticals by 74.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,062 shares of the biopharmaceutical company's stock worth $485,000 after buying an additional 880 shares in the last quarter. Natixis Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 4.5% during the fourth quarter. Natixis Advisors LLC now owns 10,453 shares of the biopharmaceutical company's stock valued at $2,460,000 after buying an additional 451 shares during the last quarter. Finally, Poinciana Advisors Group LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $203,000. Institutional investors own 92.97% of the company's stock.

Remove Ads

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,234 shares of company stock valued at $19,958,097. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Up 2.6 %

NASDAQ ALNY traded up $7.36 on Monday, reaching $290.70. 1,767,978 shares of the stock traded hands, compared to its average volume of 806,053. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a fifty day moving average price of $257.16 and a 200-day moving average price of $259.74. The company has a market cap of $37.63 billion, a price-to-earnings ratio of -133.96 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ALNY. Scotiabank upped their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a "sector outperform" rating in a report on Friday. Wells Fargo & Company increased their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday. HC Wainwright upped their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a research report on Monday, February 24th. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $280.00 to $328.00 in a research report on Monday. Finally, Needham & Company LLC restated a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $312.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.